Objective:To analyze the clinical therapeutic effect and safety of large dosage of valsartan on chronic heart failure (CHF).Methods:A total of 106 CHF patients hospitalized in our department were chosen and ran-domly divided into routine dose group (n=53,received routine dosage of valsartan,80mg,once/d)and large dose group (n=53,received large dosage of valsartan,80mg,twice/d)accerding to number table.Both groups received anti-heart failure treatment for six months according to the guidelines.After treatment,plasma N terminal pro brain natriuretic peptide (NT-proBNP)level was measured,left ventricular end-systolic diameter (LVESd),left ventricu-lar end-diastolic diameter (LVEDd),interventricular septal thickness (IVST)and left ventricular posterior wall thickness (LVPWT)were measured by color Doppler echocardiography,and all patients received 6min walking test. Therapeutic effect and incidence rates of adverse reactions were compared and analyzed between two groups after treatment.Results: Compared with routine dose group,there were significant reductions in NT-proBNP level [(3042.6±116.3)pmol/L vs.(2565.8±98.2)pmol/L],LVESd [(34.5±2.2)mm vs.(29.4± 2.0)mm], LVEDd [(55.1±2.9)mm vs.(50.2±2.5)mm],IVST [(12.9±1.8)mm vs.(10.7±1.2)mm]and LVPWT [(11.8±1.1)mm vs.(10.9±0.9)mm];significant rise in 6min walking distance [(271.2±24.9)m vs.(367.7 ±22.3)m]and total effective rate (43.40% vs.62.26%)in large dose group,P <0.05 all.There was no signifi-cant difference in incidence rates of major adverse reactions between two groups (P >0.05).Conclusion:Large dos-age of valsartan is more effective and is safe in treatment of chronic heart failure.

Objective: To study the correlation between angiotensin II type1 receptor autoantibodies (AT1-AAs) and the onset risk in patients with essential hypertension (EH) combiningacute coronary syndrome (ACS). Methods: Our research included in 4 groups: EH+ACS group,n=28, ACS group, n=29, EH group,n=26 and Control group,n=23 normal subjects. Serum levels of AT1-AAs were examined by ELISA; high sensitivity C-reactive protein (hs-CRP), blood levels of lipids and glucose were also measured and compared among different groups. The correlations between AT1-AAs and blood lipids, glucose, hs-CRP were studied by multiple linear regression analysis. Results: Compared with Control group, ACS group had similar level of AT1-AAs (0.26±0.09) vs (0.21±0.06),P=0.105; while EH+ACS group and HE group had increased AT1-AAs level as (0.40±0.005) and (0.33±0.10),P=0.001 andP=0.02 respectively; AT1-AAs level was higher in EH+ACS group than HE group,P=0.044. In addition, serum AT1-AAs level was positively related to hs-CRP in EH+ACS group, ACS group and EH group (r=0.589,r=0.503 andr=0.273, allP<0.01). Conclusion: Serum AT1-AAs level was positively related to the onset risk in patients with EH combining ACS; AT1-AAs was also related to hs-CRP at certain degree.